Pomegranate Juice does not Affect the Bioavailability of Cyclosporine in Healthy Thai Volunteers

Author(s): Wirin Anlamlert, Pakawadee Sermsappasuk*

Journal Name: Current Clinical Pharmacology
Continued as Current Reviews in Clinical and Experimental Pharmacology

Volume 15 , Issue 2 , 2020


Graphical Abstract:


Abstract:

Background: It is still controversial whether pomegranate causes drug interactions. Pomegranate juice has been shown to inhibit CYP3A in-vitro and animal studies. The coadministration of pomegranate juice with cyclosporine, a narrow therapeutic drug that is the substrate of CYP3A, might lead to drug toxicity. The objective of this study is to investigate the effect of pomegranate juice on the pharmacokinetics of cyclosporine in healthy Thai volunteers.

Methods: The study design was an open-label, randomized, single dose, crossover study with a 2- week washout period. Each fasting subject received 2 microemulsion tablets of 100 mg of cyclosporine with 500 ml of pomegranate juice (test) or 500 ml of water (control). Serial blood samples were collected up to 24 h after dosing, and blood samples were analyzed for cyclosporine concentrations by using chemiluminescent microparticle immunoassay. Fourteen healthy volunteers completed the study.

Results: The 90% confidence intervals for the test/control ratio using logarithmically transformed data of area under the concentration-time curve (AUC) from time zero until the last measured concentration (AUC0-t), AUC from time zero to infinity (AUC0-∞), and maximum concentration (Cmax) were 91.6-105.6, 92.0-105.2 and 82.3-102.5, respectively. The results were within the accepted bioequivalence range for narrow therapeutic index drugs (90-111% for AUC and 80-125% for Cmax). There were no differences in adverse event between the groups.

Conclusion: Single dose administration of pomegranate juice with cyclosporine did not significantly affect the oral bioavailability of cyclosporine. However, further work is needed to thoroughly evaluate the effect of pomegranate on narrow therapeutic drugs.

Keywords: Cyclosporine, bioavailability, pomegranate, drug interaction, pharmacokinetics, healthy volunteers.

[1]
Tedesco D, Haragsim L. Cyclosporine: A review. J Transplant 2012; 2012230386
[http://dx.doi.org/10.1155/2012/230386] [PMID: 22263104]
[2]
Ozbay A, Karamperis N, Jørgensen KA. A review of the immunosuppressive activity of cyclosporine metabolites: New insights into an old issue. Curr Clin Pharmacol 2007; 2(3): 244-8.
[http://dx.doi.org/10.2174/157488407781668758] [PMID: 18690871]
[3]
Colombo D, Ammirati E. Cyclosporine in transplantation - A history of converging timelines. J Biol Regul Homeost Agents 2011; 25(4): 493-504.
[PMID: 22217983]
[4]
Mussetti A, Greco R, Peccatori J, Corradini P. Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: Where do we stand? Expert Rev Hematol 2017; 10(5): 479-92.
[http://dx.doi.org/10.1080/17474086.2017.1318054] [PMID: 28395546]
[5]
Chighizola CB, Ong VH, Meroni PL. The use of cyclosporine A in rheumatology: A 2016 comprehensive review. Clin Rev Allergy Immunol 2017; 52(3): 401-23.
[http://dx.doi.org/10.1007/s12016-016-8582-3] [PMID: 27515671]
[6]
Poddighe D, De Amici M, Marseglia GL. Spontaneous (Autoimmune) chronic urticaria in children: Current evidences, diagnostic pitfalls and therapeutic management. Recent Pat Inflamm Allergy Drug Discov 2016; 10(1): 34-9.
[http://dx.doi.org/10.2174/1872213X10666160219163502] [PMID: 26899967]
[7]
Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - A systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007; 21(5): 606-19.
[http://dx.doi.org/10.1111/j.1468-3083.2006.02023.x] [PMID: 17447974]
[8]
Llaudó I, Colom H, Giménez-Bonafé P, et al. Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study. Transpl Int 2013; 26(2): 177-86.
[http://dx.doi.org/10.1111/tri.12018] [PMID: 23216707]
[9]
Tornatore KM, Brazeau D, Dole K, et al. Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients. J Clin Pharmacol 2013; 53(10): 1039-47.
[http://dx.doi.org/10.1002/jcph.123] [PMID: 23908147]
[10]
Huang SM, Lesko LJ. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: What have we learned? J Clin Pharmacol 2004; 44(6): 559-69.
[http://dx.doi.org/10.1177/0091270004265367] [PMID: 15145962]
[11]
Schwarz UI, Johnston PE, Bailey DG, Kim RB, Mayo G, Milstone A. Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. Br J Clin Pharmacol 2006; 62(4): 485-91.
[http://dx.doi.org/10.1111/j.1365-2125.2005.02519.x] [PMID: 16995870]
[12]
Paine MF, Criss AB, Watkins PB. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther 2005; 312(3): 1151-60.
[http://dx.doi.org/10.1124/jpet.104.076836] [PMID: 15485894]
[13]
Miniscalco A, Lundahl J, Regårdh CG, Edgar B, Eriksson UG. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther 1992; 261(3): 1195-9.
[PMID: 1602384]
[14]
Edwards DJ, Bellevue FH III, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996; 24(12): 1287-90.
[PMID: 8971132]
[15]
Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: Furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997; 7(5): 391-6.
[http://dx.doi.org/10.1097/00008571-199710000-00008] [PMID: 9352575]
[16]
He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998; 11(4): 252-9.
[http://dx.doi.org/10.1021/tx970192k] [PMID: 9548795]
[17]
Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25(11): 1228-33.
[PMID: 9351897]
[18]
Langley P. Why a pomegranate? BMJ 2000; 321(7269): 1153-4.
[http://dx.doi.org/10.1136/bmj.321.7269.1153] [PMID: 11061746]
[19]
Gil MI, Tomás-Barberán FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000; 48(10): 4581-9.
[http://dx.doi.org/10.1021/jf000404a] [PMID: 11052704]
[20]
Tzulker R, Glazer I, Bar-Ilan I, Holland D, Aviram M, Amir R. Antioxidant activity, polyphenol content, and related compounds in different fruit juices and homogenates prepared from 29 different pomegranate accessions. J Agric Food Chem 2007; 55(23): 9559-70.
[http://dx.doi.org/10.1021/jf071413n] [PMID: 17914875]
[21]
Aviram M, Dornfeld L, Kaplan M, et al. Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: Studies in atherosclerotic mice and in humans. Drugs Exp Clin Res 2002; 28(2-3): 49-62.
[PMID: 12224378]
[22]
Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 2004; 23(3): 423-33.
[http://dx.doi.org/10.1016/j.clnu.2003.10.002] [PMID: 15158307]
[23]
Noda Y, Kaneyuki T, Mori A, Packer L. Antioxidant activities of pomegranate fruit extract and its anthocyanidins: Delphinidin, cyanidin, and pelargonidin. J Agric Food Chem 2002; 50(1): 166-71.
[http://dx.doi.org/10.1021/jf0108765] [PMID: 11754562]
[24]
Kim ND, Mehta R, Yu W, et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 2002; 71(3): 203-17.
[http://dx.doi.org/10.1023/A:1014405730585] [PMID: 12002340]
[25]
Hidaka M, Okumura M, Fujita K, et al. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos 2005; 33(5): 644-8.
[http://dx.doi.org/10.1124/dmd.104.002824] [PMID: 15673597]
[26]
Farkas D, Oleson LE, Zhao Y, et al. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: Comparison with grapefruit juice. J Clin Pharmacol 2007; 47(3): 286-94.
[http://dx.doi.org/10.1177/0091270006298359] [PMID: 17322140]
[27]
Misaka S, Nakamura R, Uchida S, et al. Effect of 2 weeks’ consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: An open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. Clin Ther 2011; 33(2): 246-52.
[http://dx.doi.org/10.1016/j.clinthera.2011.02.012] [PMID: 21497708]
[28]
Park S-J, Yeo C-W, Shim E-J, et al. Pomegranate juice does not affect the disposition of simvastatin in healthy subjects. Eur J Drug Metab Pharmacokinet 2016; 41(4): 339-44.
[http://dx.doi.org/10.1007/s13318-015-0263-8] [PMID: 25720525]
[29]
Khuu T, Hickey A, Deng MC. Pomegranate-containing products and tacrolimus: A potential interaction. J Heart Lung Transplant 2013; 32(2): 272-4.
[http://dx.doi.org/10.1016/j.healun.2012.10.015] [PMID: 23200637]
[30]
Shravan KY, Adukondalu D, Bhargavi LA, et al. Effect of pomegranate pretreatment on the oral bioavailability of buspirone in male albino rabbits. Daru 2011; 19(4): 266-9.
[PMID: 22615667]
[31]
Voruganti S, Rapolu K, Tota S, Yamsani SK, Yamsani MR. Effect of pomegranate juice on the pharmacokinetics of nitrendipine in rabbits. Eur J Drug Metab Pharmacokinet 2012; 37(2): 77-81.
[http://dx.doi.org/10.1007/s13318-011-0075-4] [PMID: 22101410]
[32]
Yeo C, Shon J, Liu K, Lee D, Yoon Y, Shin J. The effects of pomegranate juice on pharmacokinetics of simvastatin in healthy Korean subjects. Clin Pharmacol Ther 2006; 79(2)(Suppl. S): 23.
[http://dx.doi.org/10.1016/j.clpt.2005.12.084]
[33]
Voruganti S, Yamsani SK, Ravula SK, Gannu R, Yamsani MR. Effect of pomegranate juice on intestinal transport and pharmacokinetics of nitrendipine in rats. Phytother Res 2012; 26(8): 1240-5.
[http://dx.doi.org/10.1002/ptr.3704] [PMID: 22275232]
[34]
Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet 2010; 49(4): 207-21.
[http://dx.doi.org/10.2165/11317550-000000000-00000] [PMID: 20214406]
[35]
Tang HL, Ma LL, Xie HG, Zhang T, Hu YF. Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: A meta-analysis. Pharmacogenet Genomics 2010; 20(9): 525-31.
[http://dx.doi.org/10.1097/FPC.0b013e32833ccd56] [PMID: 20588203]
[36]
Eng HS, Mohamed Z, Calne R, et al. The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int 2006; 69(10): 1858-64.
[http://dx.doi.org/10.1038/sj.ki.5000325] [PMID: 16612333]
[37]
Sun B, Guo Y, Gao J, et al. Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients. Pharmacogenomics 2017; 18(16): 1503-13.
[http://dx.doi.org/10.2217/pgs-2017-0127] [PMID: 28952408]
[38]
Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 1997; 32(6): 481-95.
[http://dx.doi.org/10.2165/00003088-199732060-00004] [PMID: 9195117]
[39]
Cvetković M, Zivković M, Bundalo M, et al. Effect of age and allele variants of CYP3A5, CYP3A4, and POR genes on the pharmacokinetics of cyclosporin A in pediatric renal transplant recipients from Serbia. Ther Drug Monit 2017; 39(6): 589-95.
[http://dx.doi.org/10.1097/FTD.0000000000000442] [PMID: 29135906]
[40]
Mirdehghan SH, Rahemi M, Serrano M, Guillén F, Martínez-Romero D, Valero D. The application of polyamines by pressure or immersion as a tool to maintain functional properties in stored pomegranate arils. J Agric Food Chem 2007; 55(3): 755-60.
[http://dx.doi.org/10.1021/jf062985v] [PMID: 17263471]
[41]
Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant 2004; 4(9): 1514-22.
[http://dx.doi.org/10.1111/j.1600-6143.2004.00539.x] [PMID: 15307840]


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 2
Year: 2020
Published on: 10 January, 2020
Page: [145 - 151]
Pages: 7
DOI: 10.2174/1574884715666200110153125

Article Metrics

PDF: 24
HTML: 1